Lynparza Breast Cancer Clinical Experience Investigation

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

NCT02894398 ·Status: COMPLETED ·Phase: PHASE2

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

NCT00494234 ·Status: COMPLETED ·Phase: PHASE2

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

NCT02444390 ·Status: COMPLETED ·Phase: NA

Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan

NCT05399329 ·Status: COMPLETED

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

NCT06962969 ·Status: COMPLETED

Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients

NCT03393845 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer

NCT02136927 ·Status: TERMINATED ·Phase: PHASE1

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

NCT01623349 ·Status: COMPLETED ·Phase: PHASE1

Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer

NCT00491816 ·Status: UNKNOWN ·Phase: PHASE2

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

NCT05599334 ·Status: COMPLETED

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer

NCT03243838 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

NCT05891093 ·Status: RECRUITING ·Phase: PHASE3

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

NCT00788931 ·Status: COMPLETED ·Phase: PHASE1

LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer

NCT04032080 ·Status: COMPLETED ·Phase: PHASE2

Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC

NCT01138046 ·Status: COMPLETED ·Phase: PHASE2

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

NCT00773344 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

NCT02057133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

NCT02632448 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast Cancer

NCT00708214 ·Status: COMPLETED ·Phase: PHASE2

A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer

NCT02763566 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer

NCT03099174 ·Status: COMPLETED ·Phase: PHASE1

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

NCT04498481 ·Status: COMPLETED

Breast Cancer With Over-expression of erbB2-BRAINSTORM

NCT01064349 ·Status: COMPLETED

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

NCT04460898 ·Status: COMPLETED